GlobeNewswire BiotechnologyDoubao · 实盘不做把握 8/10不做原因:无增量信息
北京时间·🕒 发布 20:00:00·⟳ 抓取 20:02:21·⚡ 决策 10-13 20:07:16 +4m55s·14.4 天前
Shattuck Labs宣布将在UEG Week 2026展示两份海报，但当前通稿未披露新的临床疗效或安全性数据
这条通稿的新增信息仅是学术会议展示安排和海报标题；未披露新的临床读出、注册进展、订单、授权合作或业绩指引，且SL-846所属DR3×IL-23受体双抗方向已在8月业务更新中出现，当前不具备可交易的基本面预期差。
📄 原文GlobeNewswire Biotechnology↗ 原文
Shattuck Labs Announces Two Poster Presentations at UEG Week 2026
AUSTIN, Texas and DURHAM, N.C., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck or the Company) (NASDAQ…
不做 Shattuck Labs, Inc.（STTK.US）
仅为未来学术会议海报日程，未发布可验证的临床数据、监管/合作里程碑或财务增量；当前没有可执行的正期望edge，等待10月17日至20日实际海报内容后再评估。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Shattuck Labs将在UEG Week展示SL-846及TL1A机制研究，但新闻稿本身没有数据结果或临床/监管状态升级。该事件更像未来数据日历提醒，而非可立即定价的新增利好，因此不做。
消息传播链
- 公司通过GlobeNewswire公告UEG Week两份海报的标题、展示者与时间，但没有随稿发布临床数据或商业交易。
关键理由
- 公告只确认未来海报展示安排，没有公布可改变SL-846或SL-325风险收益特征的疗效、安全性或监管结果。
- 第二份海报标题虽可能强化DR3路线相对TL1A抗体的差异化叙事，但当前仅有标题、无数据和合作验证，不能量化为收入或估值增量。
主要风险
- 若海报正式内容包含超预期的强临床前或早期临床数据，STTK可能在10月17日至20日后出现主题性重估。
- TL1A/IBD赛道情绪火热，微盘生物科技股可能仅凭会议预期发生短线波动，但该波动缺乏本通稿可验证的基本面支撑。
反向证据
- 做多前查反向 · 来源 web · 日期 2026-10-13 · 影响 weakens
未发现本次通稿包含临床终点、阳性数据、授权合作、注册推进或指引上调；缺乏做多所需的正向预期差。
检索:Shattuck Labs STTK UEG Week 2026 SL-846 data efficacy safety partnership 原文 ↗ - 做空前查反向 · 来源 web · 日期 2026-10-13 · 影响 none
公告没有披露失败、安全性问题、融资危机或核心管线证伪，不能把仅有海报日程解读为利空。
检索:Shattuck Labs UEG Week 2026 SL-846 TL1A negative trial failure safety concern 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例不足与事件本身无增量数据相互印证，最终选择AVOID，而非围绕会议日期投机开仓。
方向:未构建可用于定价的先例样本；常规会议海报日程通常不是临床状态迁移事件。
涨幅量级:没有同市场、同相位且锚定首发日程公告的干净先例可用于校准止盈止损。
形态:检索仅见多家生物科技公司常规会议展示公告，未形成可证明该类日程本身持续上涨或见光死的价格样本。
工具执行结果 · 成功 4 · 降级 0 · 失败 1 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 10 ms
{"result": "search_processed_events:agent query=`shattuck labs sl-846 soluble tl1a anti-tl1a immune complex ueg week october 2026 | shattuck labs sttk ueg week 2026 two poster presentations sl-846 dr3 il23ra`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此 - fetch_decision_experience 成功 stock_tools_inprocess · 1 ms
{ - web_search 成功 doubao_search · 2,295 ms
豆包搜索结果（原始查询:Shattuck Labs STTK UEG Week 2026 SL-846 poster TL1A October 2026；API SearchType:web） - kb_search 失败 stock_tools HTTP · 54 ms
kb_search 服务暂不可用；这不是一条知识库命中。 - web_search 成功 doubao_search · 1,998 ms
豆包搜索结果（原始查询:clinical stage biotech announces poster presentation conference stock reaction no new data preclinical poster；API SearchType:web）
原文全文
展开原文 · 2,131 字
AUSTIN, Texas and DURHAM, N.C., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck or the Company) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potential first-in-class monoclonal and bispecific DR3 blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today announced two upcoming poster presentations at United European Gastroenterology (UEG) Week 2026, taking place October 17–20, 2026, in Barcelona, Spain.
Presentation Details
Format:
Moderated poster presentation
Title:
Development and Characterization of SL-846: A Half-Life Extended, Dual-Receptor (DR3 x IL23RA) Targeting Bispecific Antibody
Presenter:
Mahmud Hussain, Ph.D., Director, R&D of Shattuck Labs
Date/Time:
October 19, 2026; 1:00–2:00 p.m. CEST
Format:
ePoster presentation
Title:
Soluble TL1A/Anti-TL1A Immune Complexes Induce De Novo Production of TL1A and Induce Anti-Drug Antibodies That Cross-Bind Approved IBD Antibodies
Presenter:
Suresh de Silva, Ph.D., Chief Scientific Officer of Shattuck Labs
Date/Time:
October 17–20, 2026 (available for viewing throughout the congress)
The posters will be available under Events & Presentations in the Investor Relations section of the Company’s website at
www.shattucklabs.com
following the congress.
About Shattuck Labs, Inc.
Shattuck Labs, Inc. is a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and bispecific DR3 blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases. Shattuck’s expertise in protein engineering and the development of novel TNF receptor therapeutics come together in its lead program, SL-325, a potentially first-in-class DR3 antagonist antibody designed to achieve a more complete blockade of the clinically validated DR3/TL1A pathway. The Company has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit:
www.ShattuckLabs.com
.
Investor & Media Contact:
Andrew R. Neill
Chief Financial Officer
Shattuck Labs, Inc.
InvestorRelations@shattucklabs.com
Presentation Details
Format:
Moderated poster presentation
Title:
Development and Characterization of SL-846: A Half-Life Extended, Dual-Receptor (DR3 x IL23RA) Targeting Bispecific Antibody
Presenter:
Mahmud Hussain, Ph.D., Director, R&D of Shattuck Labs
Date/Time:
October 19, 2026; 1:00–2:00 p.m. CEST
Format:
ePoster presentation
Title:
Soluble TL1A/Anti-TL1A Immune Complexes Induce De Novo Production of TL1A and Induce Anti-Drug Antibodies That Cross-Bind Approved IBD Antibodies
Presenter:
Suresh de Silva, Ph.D., Chief Scientific Officer of Shattuck Labs
Date/Time:
October 17–20, 2026 (available for viewing throughout the congress)
The posters will be available under Events & Presentations in the Investor Relations section of the Company’s website at
www.shattucklabs.com
following the congress.
About Shattuck Labs, Inc.
Shattuck Labs, Inc. is a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and bispecific DR3 blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases. Shattuck’s expertise in protein engineering and the development of novel TNF receptor therapeutics come together in its lead program, SL-325, a potentially first-in-class DR3 antagonist antibody designed to achieve a more complete blockade of the clinically validated DR3/TL1A pathway. The Company has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit:
www.ShattuckLabs.com
.
Investor & Media Contact:
Andrew R. Neill
Chief Financial Officer
Shattuck Labs, Inc.
InvestorRelations@shattucklabs.com
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
ce9cbf045e· 2026-10-13 20:07 · doubao / doubao-seed-evolving-latest-version · 策略包2226518bfdee当前